Pfizer Inc (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

• 年度报告（10-K）

  对公司业务、财务业绩和风险的年度概述。

  提交日期：2026-02-26

  查看文件

• 季度报告（10-Q）

  最近三个月财务表现的最新情况。

  提交日期：2026-08-04

  查看文件

• 临时报告（8-K）

  关于重大事件（如管理层变动或重要公告）的通知。

  提交日期：2026-08-04

  查看文件

• 4/1/2026POSITIVE
  Pfizer Wins €1.9 Billion Covid Vaccine Case With Poland, Romania

  Pfizer Inc. has secured a significant legal victory as a Belgian court ordered Poland and Romania to pay approximately €1.9 billion ($2.2 billion) for undelivered COVID-19 vaccines. This ruling validates Pfizer's contractual claims against the two nations, which had refused vaccine deliveries during the pandemic. The substantial payout underscores the enforceability of supply agreements and provides a positive financial and legal outcome for the pharmaceutical giant. Investors may view this as a testament to Pfizer's robust contract management and its ability to defend its commercial interests, potentially bolstering confidence in its future revenue streams and legal standing.

• 3/24/2026NEUTRAL
  Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday

  Pfizer Inc. (PFE) is among several stocks, including HSCS, ONDS, STRO, HST, CABA, INSM, and PVH, for which analysts have updated their ratings and price targets. While the title suggests a potential rally of over 34% for Pfizer, the article itself is a compilation of analyst actions without providing specific details on the rationale or consensus for each stock. Investors should consult the full list for detailed insights into individual analyst expectations and their implications for PFE and other mentioned equities.

• 3/23/2026NEGATIVE
  Pfizer’s Long-Awaited Lyme Vaccine Fails to Impress in Study

  Pfizer's experimental Lyme disease vaccine demonstrated only 73% efficacy in a pivotal study, falling short of expectations. The trial's outcome was further complicated by a lower-than-anticipated number of infections, making a robust evaluation of the vaccine's potency challenging. This disappointing result could impact Pfizer's vaccine pipeline and future revenue projections, potentially leading investors to re-evaluate the stock's growth prospects.

• 3/19/2026POSITIVE
  Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial

  Pfizer Inc. (PFE) shares saw a positive uptick following the announcement that its Talzenna and Xtandi combination therapy successfully met its primary endpoint in the Phase 3 TALAPRO-3 prostate cancer trial. This significant clinical trial success indicates a potential new, effective treatment option for patients, which could translate into substantial future revenue streams for the pharmaceutical giant. Investors will be closely monitoring the full trial data and subsequent regulatory submissions, as this development bolsters Pfizer's oncology pipeline and reinforces its market position in a critical therapeutic area.

• 3/17/2026NEUTRAL
  Should You Avoid Pfizer? Here's the Key Risk to Watch

  Pfizer Inc. is reportedly at a critical juncture, with analysts highlighting a key risk that investors should monitor. While the specific nature of this risk is not detailed in the provided snippet, the implication is that the pharmaceutical giant's future performance may hinge on factors that could lead to either significant upside or downside. Investors are advised to pay close attention to upcoming announcements or sector-wide developments that could impact Pfizer's strategic direction and financial results.

• 3/9/2026NEGATIVE
  Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?

  Pfizer Inc. reported a net loss in its latest quarterly earnings, raising concerns about its financial health. The company's payout ratio remains above 100%, indicating that dividend payments exceed earnings, a situation that is unsustainable long-term. This persistent imbalance suggests a potential dividend cut could be imminent, which would likely negatively impact investor sentiment and the stock price. Investors are closely monitoring Pfizer's ability to return to profitability and manage its dividend policy.

• 3/6/2026POSITIVE
  Pfizer Secures China Nod for Obesity Drug as Generics Loom

  Pfizer Inc. has secured approval in China for its new obesity drug, opening up a key market in a rapidly expanding sector. The approval comes as the entry of generic drugs looms, intensifying competition. For Pfizer investors, this represents a significant step in expanding the drug's global reach and solidifying its position in the obesity treatment market, potentially offsetting future competitive pressures and supporting revenue growth.

• 3/5/2026NEUTRAL
  Smart Money Is Betting Big In PFE Options

  Options analysis on Pfizer (PFE) reveals significant activity from "smart money," indicating institutional investors with informed positions. While the exact nature of their bets (bullish or bearish) isn't explicitly detailed, the high options trading volume suggests strong conviction in future price movements. This could imply that more informed traders anticipate imminent volatility or a directional shift for the stock. For retail investors, monitoring these moves can offer insights, but understanding the broader market context and the company's fundamentals is crucial before acting.

• 3/2/2026POSITIVE
  1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell

  Markets Gazette highlights a strong signal of confidence for Pfizer (PFE) stock. A prominent analyst has stated they purchased shares with no intention to sell, driven by reasons deemed highly compelling. This long-term investment perspective suggests that, beyond short-term market fluctuations, Pfizer's fundamentals—such as its robust research and development pipeline, diversified product portfolio, and consistent cash flow generation—make it an attractive option for investors seeking value and stability in the pharmaceutical sector. The expressed confidence implies enduring growth potential.

• 2/26/2026NEGATIVE
  This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

  An analyst has initiated coverage on Pfizer Inc. with a bearish note, signaling potential headwinds for the pharmaceutical giant. This move could influence investor sentiment and the performance of the PFE stock, especially in a market sensitive to expert evaluations. Analyst coverage initiations are often significant catalysts, and an initial negative assessment can lead to a reassessment of growth and profitability expectations. Investors should closely monitor the rationale behind this pessimistic outlook and its impact on Pfizer's future prospects, including progress in its product pipeline and management of key patents.